Bicara Therapeutics BCAX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$157.32M-14.0% | -$137.95M-13.5% | -$121.52M-18.4% | -$102.67M-11.2% | -$92.33M-35.8% | ||
| $130K+23.8% | $105K+36.4% | $77K+13.2% | $68K+9.7% | $62K+10.7% | ||
| $17.41M+16.0% | $15.01M+9.2% | $13.74M+13.0% | $12.16M+25.3% | $9.7M+31.1% | ||
| -$116.24M-8.8% | -$106.83M+5.4% | -$112.98M-11.9% | -$100.96M-14.4% | -$88.27M-18.1% | ||
| $340K+21.4% | $280K+241% | $82K+70.8% | $48K-28.4% | $67K-5.6% | ||
| -$217.51M+31.7% | -$318.45M-34.8% | -$236.16M— | —— | —— | ||
| $195.15M+505% | $32.26M+3,029% | $1.03M-99.7% | $334.73M-0.2% | $335.33M+0.1% | ||
| -$138.6M+64.7% | -$393.03M-55.2% | -$253.22M-177% | $328.62M-3.9% | $341.88M-3.7% | ||
| -$116.58M-8.8% | -$107.11M+5.3% | -$113.06M-11.9% | -$101M-14.3% | -$88.34M-18.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Bicara Therapeutics's cash flow data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.